ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Diagnostic utility of plasma p-tau217 differs by Alzheimer's disease tau-based subtypes.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative Analysis of Plasma Biomarkers of Alzheimer's Disease and Frontotemporal Dementia: The Dual Role of Soluble Fractalkine as a Biomarker of Frontotemporal Dementia and Its Neuroprotective Effects in Cortical Neurons "In Vitro".Life (Basel, Switzerland) · 2026Article
- Integrating neuroimaging and plasma biomarkers to predict preclinical Alzheimer's disease progression.Frontiers in neurologyArticle
- Diagnostic utility of plasma p-tau217 differs by Alzheimer's disease tau-based subtypes.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Introduction: Blood-based biomarkers, most notably plasma phosphorylated tau (p-tau)217, have transformed the diagnostic landscape of Alzheimer's disease (AD). Methods: We applied an unsupervised machine learning approach to tau positron emission tomography (PET) imaging in 606 participants (age 73.95 ± 7.72; 309 female) to identify AD subtypes. Within each subtype, we evaluated plasma p-tau217 levels, their association with regional tau PET uptake, differences between cognitively unimpaired (CU) and cognitively impaired (CI) individuals, and relationships to cognitive performance. Results: Four subtypes were identified: limbic, medial temporal lobe (MTL) sparing, posterior, and lateral temporal (l temporal). Plasma p-tau217 was elevated in CI versus CU in limbic, posterior, and l temporal subtypes and strongly associated with tau deposition and cognitive performance. In the MTL-sparing subtype, p-tau217 showed a significant association with tau but no elevation in CI and no relationship to cognition. Discussion: These findings indicate that p-tau217's diagnostic utility varies across AD subtypes, reflecting distinct biological mechanisms not captured by current blood biomarkers. Highlights: Plasma phosphorylated tau (p-tau)217 differentiated cognitively unimpaired from impaired individuals in most subtypes, with the notable limitation of the medial temporal lobe (MTL)-sparing group.P-tau217 level was linked to regional tau accumulation as measured by tau positron emission tomography, across all subtypes.The MTL-sparing subtype appeared to be unique, as p-tau217 was not elevated in cognitively impaired individuals, and there was no clear relationship between p-tau217 levels and cognitive performance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.